Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00841087 |
Recruitment Status
:
Completed
First Posted
: February 11, 2009
Results First Posted
: November 16, 2015
Last Update Posted
: March 3, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Diabetes Mellitus, Type 1 | Drug: insulin degludec Drug: insulin detemir Drug: insulin aspart | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 65 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIBA Once Daily + NovoRapid® Compared to Insulin Detemir Once Daily + NovoRapid®, All in a Basal-bolus Regimen in Subjects With Type 1 Diabetes Mellitus |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | May 2009 |
Actual Study Completion Date : | May 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: SIBA |
Drug: insulin degludec
The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
Drug: insulin aspart
Injection subcutaneously immediately before each meal.
|
Active Comparator: Insulin Detemir |
Drug: insulin detemir
Injection subcutaneously at bedtime
Drug: insulin aspart
Injection subcutaneously immediately before each meal.
|
- Rate of Major and Minor Hypoglycaemic Episodes [ Time Frame: Week 0 to Week 6 + 5 days follow up ]Observed rate of major and minor hypoglycaemic episodes per patient year (1year=365.25days) of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose ≤ 55 mg/dL.
- Rate of Nocturnal Major and Minor Hypoglycaemic Episodes [ Time Frame: Week 0 to Week 6 + 5 days follow up ]Observed rate of nocturnal major and minor hypoglycaemic episodes per patient year (1year=365.25days) of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose ≤ 55 mg/dL. Episodes were defined as nocturnal if the time of onset was between 23:00−05:59 (both inclusive).
- Number of Treatment Emergent Adverse Events (AEs) [ Time Frame: Week 0 to Week 6 + 5 days follow up ]Corresponds to number of adverse events. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.
- Change in Body Weight [ Time Frame: Week 0, Week 6 ]Observed change from baseline in body weight after 6 weeks of treatment
- Electrocardiogram (ECG) [ Time Frame: Week 0, Week 6 ]The number of subjects having a electrocardiogram (ECG) that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.
- Diastolic Blood Pressure (BP) [ Time Frame: Week 0, Week 6 ]Mean values at baseline (Week 0) and at Week 6
- Systolic Blood Pressure (BP) [ Time Frame: Week 0, Week 6 ]Mean values at baseline (Week 0) and at Week 6

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects with type 1 diabetes mellitus more than one year
- Current treatment: basal (once daily at bedtime) - bolus (three times a day just before main meals) regimen only for at least 12 weeks using a long-acting insulin analogue excluding insulin detemir or intermediate-acting insulin as a basal insulin and NovoRapid® as bolus insulin (a brand of basal insulin preparation has not been changed in the preceding 12 weeks)
- HbA1c below 10.0%
- Body Mass Index (BMI) below 30.0 kg/m^2
Exclusion Criteria:
- Known hypoglycaemia unawareness or recurrent major hypoglycaemia
- Current treatment with total insulin dose of more than 100 U or IU/day
- Current treatment or expected to start treatment with systemic corticosteroid

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00841087
Japan | |
Novo Nordisk Investigational Site | |
Chuo-ku, Tokyo, Japan, 103 0002 | |
Novo Nordisk Investigational Site | |
Ebina-shi, Japan, 243 0432 | |
Novo Nordisk Investigational Site | |
Koriyama-shi, Fukushima, Japan, 963 8851 | |
Novo Nordisk Investigational Site | |
Kumamoto-shi,Kumamoto, Japan, 862 0976 | |
Novo Nordisk Investigational Site | |
Oita-shi, Japan, 870 0039 | |
Novo Nordisk Investigational Site | |
Sapporo-shi, Hokkaido, Japan, 060 0062 | |
Novo Nordisk Investigational Site | |
Sapporo-shi, Hokkaido, Japan, 062 0007 | |
Novo Nordisk Investigational Site | |
Yokohama-shi, Japan, 235 0045 |
Study Director: | Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S |
Additional Information:
Publications of Results:
Responsible Party: | Novo Nordisk A/S |
ClinicalTrials.gov Identifier: | NCT00841087 History of Changes |
Other Study ID Numbers: |
NN1250-3569 JapicCTI-090711 ( Registry Identifier: JAPIC ) |
First Posted: | February 11, 2009 Key Record Dates |
Results First Posted: | November 16, 2015 |
Last Update Posted: | March 3, 2017 |
Last Verified: | January 2017 |
Additional relevant MeSH terms:
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Insulin, Globin Zinc |
Insulin degludec, insulin aspart drug combination Insulin Insulin Aspart Insulin, Long-Acting Insulin Detemir Hypoglycemic Agents Physiological Effects of Drugs |